title: [Indications for statin therapy in patients with acute coronary syndrome of ischemic origin].
abstract: Recent evidence has increasingly demonstrated that statins, besides reducing cholesterol levels, are as effective as other therapeutic approaches in the treatment of patients with acute coronary syndromes. Appropriate control of cardiovascular risk factors accounts for 44% of the overall reduction in mortality. The decrease in plasma cholesterol concentrations, however, remains the most effective therapeutic target, leading to a -24% reduction of total mortality. Statins have proved to be effective within the first few weeks after an acute coronary event. As a consequence, their use is recommended by current guidelines (class IB) in patients with non-ST-elevation myocardial infarction. Data from recent trials suggest that early statin therapy is a reasonable option for patients with ST-elevation myocardial infarction (class IA recommendation).
authors.affiliation: Sezione di Malattie Cardiovascolari, Dipartimento di Medicina Sperimentale ed Applicata, Università degli Studi, Brescia. riccardo.raddino@libero.it
authors.forename: Riccardo
authors.initials: R
authors.lastname: Raddino
authors.forename: Paolo
authors.initials: P
authors.lastname: Della Pina
authors.forename: Elio
authors.initials: E
authors.lastname: Gorga
authors.forename: Giorgio
authors.initials: G
authors.lastname: Caretta
authors.forename: Alberto
authors.initials: A
authors.lastname: Madureri
authors.forename: Livio
authors.initials: L
authors.lastname: Dei Cas
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000069059:Atorvastatin; D002784:Cholesterol / Q000097:blood; D004562:Electrocardiography; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000188:drug therapy* / Q000517:prevention & control; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D017035:Pravastatin / Q000008:administration & dosage / Q000627:therapeutic use*; D011758:Pyrroles / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D055502:Secondary Prevention
chemical_list: D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D002784:Cholesterol; D000069059:Atorvastatin; D017035:Pravastatin